Details of Drug

Details of Drug

 Drug General Information (ID: D0200)
  Drug Name
Bretylium
  Drug Type Small molecule
  Drug Synonymous
Bretylum; Bretylium tolsylate; Bretylium tosylate(USAN); N-(2-bromobenzyl)-N,N-dimethylethanaminium; N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminium; Benzenemethanaminium, 2-bromo-N-ethyl-N,N-dimethyl-, salt with 4-methylbenzenesulfonic acid (1:1); (2-bromobenzyl)ethyldimethylaminium; (2-bromophenyl)methyl-ethyl-dimethylazanium; (o-Bromobenzyl)ethyldimethylammonium p-toluenesulfonate; 2-bromo-N-ethyl-N,N-dimethylbenzenemethanaminium
    Click to Show/Hide
  Disease Class BC71: Ventricular tachyarrhythmia
  Therapeutic Class Antiarrhythmic Agents
  Structure Could Not Find 2D Structure
3D Structure 2D Structure
  Formula C11H17BrN+
  InChI 1S/C11H17BrN/c1-4-13(2,3)9-10-7-5-6-8-11(10)12/h5-8H,4,9H2,1-3H3/q+1
  InChIKey AAQOQKQBGPPFNS-UHFFFAOYSA-N
  Canonical SMILES CC[N+](C)(C)CC1=CC=CC=C1Br
  External Link
Pubchem ID 2431
CAS Number 59-41-6
CHEBI ID 3172
TTD ID D02YYF
VARIDT ID DR01325

Drug-Drug Interaction Network
  Sunburst Graph
AM003  Affected organization distribution
AM006  Pharmacodynamic additive effects
BM014  Interference of cell/tissue uptake
BM049  Increased risk of atrioventricular block
BM051  Increased risk of bradycardia
BM076  Increased risk of prolong QT interval
BM078  Increased risk of rapid heart rate
BM109  Increased risk of other adverse reactions (Unspecific)
  Relation Graph
 Full list of drugs interacting with Bretylium
      Affected organization distribution
   Interference of cell/tissue uptake Drug Num:  2
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0829
 
Iobenguane (I-131)
 
C8H10IN3
 
60860 
Major    Inter Info   
[7]
D1821
 
Iobenguane (I-123)
 
C8H10IN3
 
60860 
Moderate    Inter Info   
[20], [21], [22]
      Pharmacodynamic additive effects
   Increased risk of atrioventricular block Drug Num:  1
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0992
 
Mefloquine
 
C17H16F6N2O
 
4046 
Moderate    Inter Info   
[5], [30], [23]
   Increased risk of bradycardia Drug Num:  9
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0110
 
Articaine
 
C13H20N2O3S
 
32170 
Moderate    Inter Info   
[18], [19]
D0622
 
Etidocaine
 
C17H28N2O
 
37497 
Moderate    Inter Info   
[18], [19]
D1600
 
Tofacitinib
 
C16H20N6O
 
9926791 
Moderate    Inter Info   
[4], [23]
D0218
 
Bupivacaine
 
C18H28N2O
 
2474 
Moderate    Inter Info   
[18], [19]
D0916
 
Levobupivacaine
 
C18H28N2O
 
92253 
Moderate    Inter Info   
[18], [19]
D0927
 
Lidocaine
 
C14H22N2O
 
3676 
Moderate    Inter Info   
[18], [19]
D1004
 
Mepivacaine
 
C15H22N2O
 
4062 
Moderate    Inter Info   
[18], [19]
D1337
 
Prilocaine
 
C13H20N2O
 
4906 
Moderate    Inter Info   
[18], [19]
D1428
 
Ropivacaine
 
C17H26N2O
 
175805 
Moderate    Inter Info   
[18], [19]
   Increased risk of prolong QT interval Drug Num:  7
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0067
 
Amisulpride
 
C17H27N3O4S
 
2159 
Major    Inter Info   
[4], [5], [6]
D1353
 
Propafenone
 
C21H27NO3
 
4932 
Major    Inter Info   
[8], [9], [10], [11], [12], [13]
D0508
 
Disopyramide
 
C21H29N3O
 
3114 
Major    Inter Info   
[4], [14]
D0513
 
Dofetilide
 
C19H27N3O5S2
 
71329 
Major    Inter Info   
[15]
D0787
 
Ibutilide
 
C20H36N2O3S
 
60753 
Major    Inter Info   
[16], [17]
D0498
 
Dimenhydrinate
 
C24H28ClN5O3
 
10660 
Moderate    Inter Info   
[4], [27], [28], [29]
D0502
 
Diphenhydramine
 
C17H21NO
 
3100 
Moderate    Inter Info   
[4], [27], [28], [29]
   Increased risk of rapid heart rate Drug Num:  1
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0101
 
Arbutamine
 
C18H23NO4
 
60789 
Major    Inter Info   
[1], [2], [3]
   Increased risk of other adverse reactions (Unspecific) Drug Num:  1
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0491
 
Digoxin
 
C41H64O14
 
2724385 
Moderate    Inter Info   
[24], [25], [26]
References
1 Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90. [PMID: 6882885]
2 Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76. [PMID: 8739026]
3 Product Information. GenESA (arbutamine). Gensia Inc, San Diego, CA.
4 Cerner Multum, Inc. "Australian Product Information.".
5 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
6 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
7 Product Information. Azedra (iobenguane I-131). Progenics Pharmaceuticals, Inc., New York, NY.
8 Buss J, Neuss H, Bilgin Y, Schlepper M "Malignant ventricular tachyarrhythmias in association with propafenone treatment." Eur Heart J 6 (1985): 424-8. [PMID: 4043097]
9 Hii JT, Wyse DG, Gillis AM, et al "Propafenone-induced torsade de pointes: cross-reactivity with quinidine." Pacing Clin Electrophysiol 14 (1991): 1568-70. [PMID: 1721143]
10 Klein RC, Huang SK, Marcus FI, et al "Enhanced antiarrhythmic efficacy of propafenone when used in combination with procainamide or quinidine." Am Heart J 114 (1987): 551-8. [PMID: 3630896]
11 Product Information. Rhythmol (propafenone). Knoll Pharmaceutical Company, Whippany, NJ.
12 Product Information. Rythmol SR (propafenone). GlaxoSmithKline, Research Triangle Park, NC.
13 Zehender M, Hohnloser S, Geibel A, et al "Short-term and long-term treatment with propafenone: determinants of arrhythmia suppression, persistence of efficacy, arrhythmogenesis, and side effects in patients." Br Heart J 67 (1992): 491-7. [PMID: 1622701]
14 Product Information. Norpace (disopyramide). Searle, Skokie, IL.
15 Product Information. Tikosyn (dofetilide) Pfizer US Pharmaceuticals, Atlanta, GA.
16 Canadian Pharmacists Association.
17 Product Information. Corvert (ibutilide). Pharmacia and Upjohn, Kalamazoo, MI.
18 Keidar S, Grenadier E, Palant A "Sinoatrial arrest due to lidocaine injection in sick sinus syndrome during amiodarone administration." Am Heart J 104 (1982): 1384-5. [PMID: 7148661]
19 Product Information. Naropin (ropivacaine). Astra USA, Westborough, MA.
20 Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
21 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
22 Product Information. AdreView (iobenguane I-123). GE Healthcare, Princeton, NJ.
23 Canadian Pharmacists Association "e-CPS."
24 Darcy PF "Nutrient-drug interactions." Adverse Drug React Toxicol Rev 14 (1995): 233-54. [PMID: 8845456]
25 Heissenbuttel RH, Bigger JT Jr "Bretylium tosylate: a newly available antiarrhythmic drug for ventricular arrhythmias." Ann Intern Med 91 (1979): 229-38
26 Product Information. Bretylol (bretylium). DuPont Pharmaceuticals, Wilmington, DE.
27 Husain Z, Hussain K, Nair R, Steinman R "Diphenhydramine induced QT prolongation and torsade de pointes: An uncommon effect of a common drug." Cardiology 17 (2010): 509-11. [PMID: 20865683]
28 Poluzzi E, Raschi E, Godman B, et.al "Pro-arrhythmic potential of oral antihistamines (H1): Combining adverse event reports with drug utilization data across Europe." PLoS One 10 (2014): epub. [PMID: 25785934]
29 Shah A, Yousuf T, Ziffra J, Zaidi A, Raghuvir R "Diphenhydramine and QT prolongation - A rare cardiac side effect of a drug used in common practice." J Cardiol Cases 12 (2015): 126-9. [PMID: 30546575]
30 Product Information. Lariam (mefloquine). Roche Laboratories, Nutley, NJ.